Monograph
A10BB12 - Glimepiride |
Propably not porphyrinogenic |
PNP |
Rationale
Glimepiride is metabolized by CYP2C9. There are no clinical studies indicating that glipizide is an inhibitor or inducer of CYP enzymes.
Chemical description
Sulfonylourea.
Therapeutic characteristics
Glimepirid is indicated for the treatment of diabetes type 2.
Very rare side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea and abdominal pain. A rare side effect is hypoglycaemia, which also may be potentially porphyrinogenic.
Metabolism and pharmacokinetics
Glimepirid is metabolized mainly by CYP2C9 (Holstein 2012) and the elimination half-life is 5-8 hours.
There are no clinical studies indicating that glipizide is an inhibitor or inducer of CYP enzymes.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
Holstein A, Beil W, Kovacs P. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1549-63. |
23153186 |
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). (glimepirid).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024